Diagnostic marker and platform for drug design in myocardial infarction and heart failure
A technology for myocardial infarction and heart disease, applied in the field of diagnostic markers and drug design platforms in myocardial infarction and heart failure, can solve problems such as reducing ejection fraction and increasing end-diastolic volume
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment Construction
[0156] Patients and methods
[0157] In order to increase our chances of detecting relevant SNPs in the context of ventricular remodeling, we selected two groups of patients with "extreme" phenotypes after myocardial infarction, that is, patients who developed very smoothly after infarction (EF> 55%, average 60%) and Patients with poor development (EF<40%, mean 29%). Each group contains 22 patients.
[0158] Genomic DNA was extracted from peripheral blood mononuclear cells after Ficoll was isolated. The extraction was performed using FlexiGene DNA kit (Qiagen) according to the manufacturer's instructions. The quantity and quality of DNA were evaluated using Nanodrop spectrophotometer. DNA integrity was assessed by agarose gel electrophoresis.
[0159] Without knowing the patient's phenotype, the entire MMP-9 gene was sequenced in all patients, including the promoter, coding sequence, and untranslated region (9kb in total).
[0160] The plasma MMP-9 level was determined by gelatin ...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com